Trade Eurofins Scientific - ERFp CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.40 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024161% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.020283% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 0.1 | ||||||||
Currency | EUR | ||||||||
Margin | 20% | ||||||||
Stock exchange | France | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Eurofins Scientific SE ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 68 |
Open* | 67.55 |
1-Year Change* | -25.32% |
Day's Range* | 67.35 - 68.5 |
52 wk Range | 58.06-100.50 |
Average Volume (10 days) | 520.50K |
Average Volume (3 months) | 9.60M |
Market Cap | 13.08B |
P/E Ratio | 16.48 |
Shares Outstanding | 192.34M |
Revenue | 6.86B |
EPS | 4.12 |
Dividend (Yield %) | 1.47406 |
Beta | 0.42 |
Next Earnings Date | Feb 22, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 7, 2023 | 68.00 | -0.20 | -0.29% | 68.20 | 68.80 | 67.15 |
Feb 6, 2023 | 70.90 | 0.30 | 0.42% | 70.60 | 71.95 | 70.35 |
Feb 3, 2023 | 70.85 | 2.25 | 3.28% | 68.60 | 71.00 | 68.50 |
Feb 2, 2023 | 68.90 | 2.55 | 3.84% | 66.35 | 69.00 | 66.15 |
Feb 1, 2023 | 65.25 | -0.70 | -1.06% | 65.95 | 66.70 | 65.00 |
Jan 31, 2023 | 65.55 | 0.30 | 0.46% | 65.25 | 65.60 | 64.25 |
Jan 30, 2023 | 65.75 | 0.70 | 1.08% | 65.05 | 65.95 | 64.55 |
Jan 27, 2023 | 65.30 | 0.35 | 0.54% | 64.95 | 65.50 | 64.10 |
Jan 26, 2023 | 64.75 | 0.30 | 0.47% | 64.45 | 64.95 | 63.85 |
Jan 25, 2023 | 63.50 | -0.30 | -0.47% | 63.80 | 63.90 | 62.80 |
Jan 24, 2023 | 64.15 | -0.30 | -0.47% | 64.45 | 65.00 | 63.65 |
Jan 23, 2023 | 64.30 | 0.25 | 0.39% | 64.05 | 64.35 | 63.35 |
Jan 20, 2023 | 63.70 | -0.45 | -0.70% | 64.15 | 64.70 | 63.55 |
Jan 19, 2023 | 64.25 | -1.70 | -2.58% | 65.95 | 66.20 | 63.85 |
Jan 18, 2023 | 66.55 | 0.35 | 0.53% | 66.20 | 67.00 | 66.05 |
Jan 17, 2023 | 65.75 | 1.30 | 2.02% | 64.45 | 65.95 | 64.25 |
Jan 16, 2023 | 64.80 | 0.10 | 0.15% | 64.70 | 65.80 | 64.50 |
Jan 13, 2023 | 64.25 | -0.15 | -0.23% | 64.40 | 64.65 | 63.95 |
Jan 12, 2023 | 64.90 | 1.40 | 2.20% | 63.50 | 65.00 | 63.45 |
Jan 11, 2023 | 63.20 | -1.05 | -1.63% | 64.25 | 64.80 | 62.75 |
Eurofins Scientific Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 2536.61 | 2971.42 | 3781.15 | 4562.8 | 5438.8 | 6717.7 |
Revenue | 2536.61 | 2971.42 | 3781.15 | 4562.8 | 5438.8 | 6717.7 |
Cost of Revenue, Total | 2056.98 | 2414.69 | 3061.3 | 3632.1 | 4026.1 | 4816 |
Gross Profit | 479.624 | 556.723 | 719.845 | 930.7 | 1412.7 | 1901.7 |
Total Operating Expense | 2178.99 | 2571.85 | 3260.39 | 3989.3 | 4415.2 | 5244.9 |
Selling/General/Admin. Expenses, Total | 0 | 0 | 0 | |||
Depreciation / Amortization | 122.008 | 157.161 | 199.085 | 357.2 | 389.1 | 428.9 |
Other Operating Expenses, Total | 0.001 | |||||
Operating Income | 357.615 | 399.562 | 520.76 | 573.5 | 1023.6 | 1472.8 |
Interest Income (Expense), Net Non-Operating | -68.698 | -42.74 | -59.717 | -93.2 | -97.5 | -97 |
Other, Net | 19.91 | 0.001 | -0.001 | -3.1 | -5.9 | -7 |
Net Income Before Taxes | 308.827 | 356.823 | 461.042 | 477.2 | 920.2 | 1368.8 |
Net Income After Taxes | 227.465 | 302.341 | 356.061 | 360.3 | 707.2 | 1043.4 |
Minority Interest | -3.509 | -2.074 | 0.358 | 0 | -1 | -0.4 |
Net Income Before Extra. Items | 223.956 | 300.267 | 356.419 | 360.3 | 706.2 | 1043 |
Total Extraordinary Items | -49.959 | -83.496 | -132.476 | -165 | -166.7 | -260 |
Net Income | 173.997 | 216.771 | 223.943 | 195.3 | 539.5 | 783 |
Total Adjustments to Net Income | -35.625 | -37.335 | -48.624 | -49.8 | -34.2 | -34.5 |
Income Available to Common Excl. Extra. Items | 188.331 | 262.932 | 307.795 | 310.5 | 672 | 1008.5 |
Income Available to Common Incl. Extra. Items | 138.372 | 179.436 | 175.319 | 145.5 | 505.3 | 748.5 |
Dilution Adjustment | 0 | 0 | 0 | |||
Diluted Net Income | 138.372 | 179.436 | 175.319 | 145.5 | 505.3 | 748.5 |
Diluted Weighted Average Shares | 169.57 | 179.98 | 183.01 | 186 | 195.9 | 200.6 |
Diluted EPS Excluding Extraordinary Items | 1.11064 | 1.4609 | 1.68185 | 1.66935 | 3.43032 | 5.02742 |
Dividends per Share - Common Stock Primary Issue | 0.2 | 0.24 | 0.288 | 0 | 0.68 | 1 |
Diluted Normalized EPS | 1.11064 | 1.4609 | 1.68185 | 1.66935 | 3.43032 | 5.02742 |
Q2 2021 | Q4 2021 | |
---|---|---|
Total revenue | 3272.3 | 3445.4 |
Revenue | 3272.3 | 3445.4 |
Cost of Revenue, Total | 2264.2 | 2551.8 |
Gross Profit | 1008.1 | 893.6 |
Total Operating Expense | 2459 | 2785.9 |
Selling/General/Admin. Expenses, Total | 0 | 0 |
Depreciation / Amortization | 194.8 | 234.1 |
Operating Income | 813.3 | 659.5 |
Interest Income (Expense), Net Non-Operating | -49.6 | -54.4 |
Net Income Before Taxes | 763.7 | 605.1 |
Net Income After Taxes | 582.9 | 460.5 |
Minority Interest | -0.4 | 0 |
Net Income Before Extra. Items | 582.5 | 460.5 |
Total Extraordinary Items | -166.9 | -93.1 |
Net Income | 415.6 | 367.4 |
Total Adjustments to Net Income | -18.2 | -16.3 |
Income Available to Common Excl. Extra. Items | 564.3 | 444.2 |
Income Available to Common Incl. Extra. Items | 397.4 | 351.1 |
Diluted Net Income | 397.4 | 351.1 |
Diluted Weighted Average Shares | 201 | 200.2 |
Diluted EPS Excluding Extraordinary Items | 2.80746 | 2.21878 |
Dividends per Share - Common Stock Primary Issue | 0 | 1 |
Diluted Normalized EPS | 2.80746 | 2.21878 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 1579.41 | 1826.58 | 1705.4 | 1604.1 | 2518.2 | 2319 |
Cash and Short Term Investments | 826.098 | 820.357 | 506.246 | 297 | 912.4 | 515.3 |
Cash | 506.019 | 153.293 | 24.599 | 293.4 | 903.7 | 497.9 |
Cash & Equivalents | 320.079 | 667.064 | 481.647 | 3.6 | 8.7 | 17.4 |
Total Receivables, Net | 605.782 | 826.799 | 1043.32 | 1185 | 1389.1 | 1581 |
Accounts Receivable - Trade, Net | 498.014 | 666.828 | 807.233 | 1001.2 | 1193.5 | 1389.2 |
Total Inventory | 39.547 | 51.805 | 66.373 | 79.3 | 157 | 154.2 |
Prepaid Expenses | 22.432 | 37.14 | 42.668 | 42.6 | 59.6 | 68 |
Other Current Assets, Total | 85.554 | 90.477 | 46.796 | 0.2 | 0.1 | 0.5 |
Total Assets | 4129.42 | 5832.31 | 7205.45 | 7823.1 | 8575.5 | 9332.3 |
Property/Plant/Equipment, Total - Net | 506.818 | 685.998 | 1018.01 | 1593.5 | 1574.9 | 1829.9 |
Property/Plant/Equipment, Total - Gross | 1242.93 | 1661.55 | 2151.32 | 3171.5 | 3344.9 | 4020.7 |
Accumulated Depreciation, Total | -736.11 | -975.549 | -1133.31 | -1578 | -1769.9 | -2190.8 |
Goodwill, Net | 1584.64 | 2505.34 | 3418.33 | 3608.8 | 3524.1 | 4115.1 |
Intangibles, Net | 383.209 | 735.12 | 946.918 | 918.2 | 825.1 | 895.7 |
Long Term Investments | 37.527 | 49.584 | 72.626 | 54.5 | 56.6 | 81.7 |
Other Long Term Assets, Total | 37.804 | 29.69 | 44.169 | 44 | 76.6 | 90.9 |
Total Current Liabilities | 710.009 | 1451.89 | 1450.66 | 1581.6 | 1696.4 | 1855.7 |
Payable/Accrued | 230.122 | -0.1 | ||||
Accrued Expenses | 278.76 | 435.633 | 560.803 | 623.7 | 796.6 | 874.6 |
Notes Payable/Short Term Debt | -1.215 | 234.331 | 372.243 | 319.5 | 16.9 | 80.3 |
Current Port. of LT Debt/Capital Leases | 44.734 | 319.9 | 18.832 | 135.3 | 220.7 | 173.5 |
Other Current Liabilities, Total | 157.608 | 255.886 | 266.84 | 271.6 | 383.4 | 404.4 |
Total Liabilities | 2501.94 | 3389.14 | 4536.26 | 4984.5 | 4885.2 | 4684.6 |
Total Long Term Debt | 1340.36 | 1662.1 | 2766.17 | 3086.9 | 2917.2 | 2500.3 |
Long Term Debt | 1331.89 | 1651.54 | 2727.22 | 2646.8 | 2502.4 | 2082.1 |
Capital Lease Obligations | 8.472 | 10.558 | 38.946 | 440.1 | 414.8 | 418.2 |
Deferred Income Tax | 83.911 | 126.352 | 138.557 | 124.5 | 115.3 | 123.6 |
Minority Interest | 129.237 | 38.803 | 52.992 | 59.5 | 26.1 | 29.5 |
Other Liabilities, Total | 238.422 | 109.99 | 127.88 | 132 | 130.2 | 175.5 |
Total Equity | 1627.48 | 2443.17 | 2669.19 | 2838.6 | 3690.3 | 4647.7 |
Common Stock | 1.693 | 1.764 | 1.775 | 1.8 | 1.9 | 1.9 |
Retained Earnings (Accumulated Deficit) | 902.209 | 1457.74 | 1614.03 | 1697.1 | 2853.1 | 3542.7 |
Other Equity, Total | 723.575 | 983.668 | 1053.57 | 1139.9 | 835.3 | 1106.7 |
Total Liabilities & Shareholders’ Equity | 4129.42 | 5832.31 | 7205.45 | 7823.1 | 8575.5 | 9332.3 |
Total Common Shares Outstanding | 169.26 | 176.439 | 177.522 | 179.035 | 190.794 | 192.214 |
Accounts Payable | 206.143 | 231.942 | 231.5 | 278.9 | 322.9 | |
Treasury Stock - Common | -0.184 | -0.2 | 0 | -3.6 |
Jun 2021 | Dec 2021 | |
---|---|---|
Total Current Assets | 2412.9 | 2319 |
Cash and Short Term Investments | 639.9 | 515.3 |
Cash & Equivalents | 639.9 | 515.3 |
Total Receivables, Net | 1405.3 | 1465.9 |
Accounts Receivable - Trade, Net | 1316 | 1389.2 |
Total Inventory | 169.1 | 154.2 |
Prepaid Expenses | 198.4 | 183.1 |
Other Current Assets, Total | 0.2 | 0.5 |
Total Assets | 8661 | 9332.3 |
Property/Plant/Equipment, Total - Net | 1667.3 | 1829.9 |
Goodwill, Net | 3643.3 | 4115.1 |
Intangibles, Net | 814.9 | 895.7 |
Long Term Investments | 61.5 | 81.7 |
Other Long Term Assets, Total | 61.1 | 90.9 |
Total Current Liabilities | 1758.1 | 1855.7 |
Payable/Accrued | 530.8 | 627.6 |
Accrued Expenses | 44.4 | 31.4 |
Notes Payable/Short Term Debt | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 128.2 | 253.8 |
Other Current Liabilities, Total | 1054.7 | 942.9 |
Total Liabilities | 4581.8 | 4684.6 |
Total Long Term Debt | 2526.8 | 2500.3 |
Long Term Debt | 2526.8 | 2500.3 |
Deferred Income Tax | 116.2 | 123.6 |
Minority Interest | 31 | 29.5 |
Other Liabilities, Total | 149.7 | 175.5 |
Total Equity | 4079.2 | 4647.7 |
Common Stock | 1.9 | 1.9 |
Retained Earnings (Accumulated Deficit) | 3132.2 | 3542.7 |
Other Equity, Total | 945.1 | 1106.7 |
Total Liabilities & Shareholders’ Equity | 8661 | 9332.3 |
Total Common Shares Outstanding | 191.329 | 192.214 |
Treasury Stock - Common | -3.6 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 242.607 | 250.105 | 289.84 | 271.5 | 694.4 | 1056.6 |
Cash From Operating Activities | 371.841 | 405.122 | 543.894 | 677.8 | 1223.5 | 1509.9 |
Cash From Operating Activities | 141.696 | 175.718 | 223.747 | 395.9 | 426 | 450.7 |
Non-Cash Items | 67.414 | 28.645 | 41.124 | 69.6 | 142.8 | 207 |
Cash Taxes Paid | 73.239 | 79.384 | 67.816 | 95 | 94 | 296.7 |
Cash Interest Paid | 55.222 | 45.612 | 59.983 | 93.3 | 67.8 | 168.8 |
Changes in Working Capital | -79.876 | -90.121 | -88.622 | -159.2 | -142.5 | -302 |
Cash From Investing Activities | -391.803 | -1747.09 | -1557.45 | -540.2 | -525 | -1034.2 |
Capital Expenditures | -199.675 | -245.735 | -364.449 | -425.1 | -355.5 | -519.5 |
Other Investing Cash Flow Items, Total | -192.128 | -1501.35 | -1193 | -115.1 | -169.5 | -514.7 |
Cash From Financing Activities | 49.903 | 1343.29 | 691.064 | -342.2 | -48.6 | -910.3 |
Financing Cash Flow Items | -90.849 | 317.307 | -108.706 | -461.9 | -104.5 | -335.4 |
Total Cash Dividends Paid | -22.452 | -34.912 | -42.645 | -51.1 | ||
Issuance (Retirement) of Stock, Net | 501.118 | 320.049 | 20.041 | 23.4 | 564.8 | 32.2 |
Issuance (Retirement) of Debt, Net | -337.914 | 740.848 | 822.374 | 147.4 | -508.9 | -607.1 |
Foreign Exchange Effects | 4.674 | -10.969 | 1.465 | 4.1 | -33.9 | 39.1 |
Net Change in Cash | 34.615 | -9.641 | -321.023 | -200.5 | 616 | -395.5 |
Amortization | 40.775 | 77.805 | 100 | 102.8 | 97.6 |
Jun 2021 | Dec 2021 | |
---|---|---|
Net income/Starting Line | 578.8 | 1056.6 |
Cash From Operating Activities | 708.6 | 1509.9 |
Cash From Operating Activities | 204.4 | 450.7 |
Non-Cash Items | 192.8 | 304.6 |
Cash Taxes Paid | 139.9 | 296.7 |
Cash Interest Paid | 135.8 | 168.8 |
Changes in Working Capital | -267.4 | -302 |
Cash From Investing Activities | -276.5 | -1034.2 |
Capital Expenditures | -223 | -519.5 |
Other Investing Cash Flow Items, Total | -53.5 | -514.7 |
Cash From Financing Activities | -718.7 | -910.3 |
Financing Cash Flow Items | -150.4 | -335.4 |
Total Cash Dividends Paid | -0.4 | |
Issuance (Retirement) of Stock, Net | 12.6 | 32.2 |
Issuance (Retirement) of Debt, Net | -580.5 | -607.1 |
Foreign Exchange Effects | 14.7 | 39.1 |
Net Change in Cash | -271.9 | -395.5 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Family (Gilles Martin) | Other Insider Investor | 32.7621 | 63145480 | 0 | 2022-10-24 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.6517 | 5110825 | 497156 | 2022-12-31 | LOW |
Capital Research Global Investors | Investment Advisor | 2.1126 | 4071885 | 2346140 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.772 | 3415358 | 186 | 2022-12-31 | LOW |
Allianz Global Investors GmbH | Investment Advisor | 1.7115 | 3298735 | 10351 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.4551 | 2804489 | 130325 | 2022-12-31 | LOW |
Impax Asset Management Ltd. | Investment Advisor | 1.3688 | 2638300 | 0 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.3249 | 2553659 | 13084 | 2023-01-31 | LOW |
FMR Investment Management (U.K.) Limited | Investment Advisor | 1.3171 | 2538574 | -9500 | 2022-12-31 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.2415 | 2392913 | 380 | 2022-12-31 | LOW |
1832 Asset Management L.P. | Investment Advisor | 1.1023 | 2124655 | 314999 | 2022-09-30 | LOW |
Mawer Investment Management Ltd. | Investment Advisor | 1.0868 | 2094699 | 38093 | 2022-12-31 | LOW |
Ruane, Cunniff & Goldfarb L.P. | Investment Advisor | 0.9979 | 1923273 | 415107 | 2022-09-30 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.9334 | 1799105 | 64223 | 2022-12-31 | HIGH |
T. Rowe Price Associates, Inc. | Investment Advisor | 0.8623 | 1662046 | -845338 | 2022-12-31 | LOW |
Jupiter Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.7381 | 1422581 | 2545 | 2022-10-31 | LOW |
Union Investment Privatfonds GmbH | Investment Advisor | 0.6808 | 1312181 | -110462 | 2022-09-30 | LOW |
T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 0.6156 | 1186565 | 69099 | 2022-12-31 | MED |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 0.5994 | 1155282 | 1954 | 2022-12-31 | LOW |
Oddo BHF Asset Management S.A.S | Investment Advisor/Hedge Fund | 0.5596 | 1078488 | 0 | 2022-12-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Eurofins Company profile
Eurofins Scientific is an international laboratory testing company, founded in 1987 and headquartered in Luxembourg. Through its subsidiaries, the company offers environmental, pharmaceutical products and food testing, as well as the key emerging specialty clinical diagnostic testing.
The company prides itself on performing over 400 million tests each year and holding over 200,000 validated analytical methods in its portfolio. With over 45,000 employees, Eurofins Scientific operates a global network of 800 laboratories in 47 countries.
Eurofins operates through an extensive network of laboratories, including Institut Nehring GmbH in Germany, VRL Laboratories in the United States, Agfirst Bay of Plenty, a fruit maturity testing laboratory in New Zealand, and Megalab SA, a clinical diagnostic laboratory in Spain. Eurofins also have subsidiaries in Eastern Canada, Brazil, and Japan.
One of the fastest-growing companies in Europe, Eurofins Scientific is known for its aggressive expansion strategy, as it has bought more than 80% of its competitors worldwide. Since it went public in 1997 on the French stock exchange, Eurofins has been reporting a 35% growth in sales each year with 3.7 billion Euro in 2018.
The Eurofins share price is quoted on Euronext Paris and featured in the CAC Mid 60 Index. Find out an updated Eurofins company profile, the latest company news and the most current Eurofins share price data at Capital.com.
Industry: | Testing Laboratories |
23 Val Fleuri
LUXEMBOURG
1526
LU
Income Statement
- Annual
- Quarterly
News

Markets look for guidance after Powell speech, eyeing US CPI: USD, S&P 500, DAX 40
Us equities try to build appetite to push higher after Powell acknowledges disinflation during his speech
12:34, 8 February 2023
Ripple/SEC Lawsuit: News And Update
Ripple and the US Securities and Exchange Commission are still awaiting a ruling
15:00, 7 February 2023
Gold Price Forecast: Gold Loses Shine as USD and US Yields Edge Higher
Gold correcting lower on USD comeback. Eyes on Chair Powell to exacerbate Gold downside
12:41, 7 February 2023
Australian Dollar Outlook: AUD/USD bounces back as RBA hikes 25bps
AUS/USD bounces higher as RBA delivers its 9th rate hike
11:28, 7 February 2023
Japanese Yen Outlook: USD/JPY Edging Towards YTD Peak on BoJ Dove and US Yields
Japanese Yen underperforms with BoJ dove touted to be Governor Kuroda successor.
14:36, 6 February 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com